Antiphospholipid (Hughes) syndrome (Q35934717)

11 August 2017

1 reference

title

Antiphospholipid (Hughes) syndrome (English)

1 reference

11 August 2017

1

Munther A Khamashta

1 reference

11 August 2017

3

Graham R V Hughes

1 reference

11 August 2017

Maria Laura Bertolaccini

series ordinal

2

object named as

Maria Laura Bertolaccini

1 reference

11 August 2017

publication date

1 June 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

37

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

309-312

1 reference

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Genetics of antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Antiphospholipid syndrome: obstetric diagnosis, management, and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930410001708706

10.1080/08916930410001708706

21 January 2018

Identifiers

DOI

1 reference

release_wgc43l232fh6vkinetgn6srx6i

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wgc43l232fh6vkinetgn6srx6i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference